Navigation Links
Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
Date:12/1/2011

PITTSBURGH, Dec. 1, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and Famy Care Ltd. have been sued by Warner Chilcott Company LLP, in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets, 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This product is the generic version of Generess™ Fe, a 28-day regimen indicated for use by women to prevent pregnancy.

Mylan believes that this application submitted to the FDA is the first substantially complete ANDA containing a Paragraph IV certification and expects it to qualify for 180 days of marketing exclusivity upon final approval. In 2008, Mylan and Famy Care entered into a partnership to develop and supply oral contraceptives. Warner Chilcott filed the lawsuit in the U.S. District Court for the District of New Jersey.

Since launching in April 2011 and through Sept. 30, 2011, Generess Fe had sales of $4.5 million, according to IMS Health.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first-to-file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
2. Mylan Receives Approval for Generic Version of Zinecard® for Injection
3. Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot®
4. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
5. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
6. Mylan to Acquire Pfizer Respiratory Delivery Platform
7. Mylan Receives Approval for Generic Version of MS Contin® Tablets
8. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
9. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
10. Matrix Laboratories Completes Name Change to Mylan Laboratories
11. Mylan Announces Femcon® Fe Settlement Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, households ... mail from USA Medical Prescription Assistance Program. They are customized to reflect the ... package will include a ready-to-use, state-themed card and, in the near future, material ...
(Date:4/28/2016)... ... April 28, 2016 , ... The Aging in Motion Coalition ... an ICD-10-CM code for sarcopenia, giving it recognition for separate reporting and data collection. ... 1, 2016. , Sarcopenia is defined as a combination of low muscle mass and ...
(Date:4/28/2016)... ... April 28, 2016 , ... North Hollywood dentist , Dr. Hamid ... is essential when it comes to dental accidents or critical dental problems. These issues ... losing a tooth. Toothaches, knocked-out teeth, chipped teeth, and many other issues can lead ...
(Date:4/28/2016)... (PRWEB) , ... April 28, ... ... an invitation to those affected by a health insurance co-operative bankruptcy to ... proprietary process, individuals can receive over 1,500 FDA-approved prescription medications from over ...
(Date:4/28/2016)... , ... April 28, 2016 , ... For many, a diet is only as good ... if it does not look good. In addition, an individual cannot deny the importance of ... , The team, therefore, has worked to create a product range that could entice people ...
Breaking Medicine News(10 mins):